A Phoenix? Thalidomide Returns As An Exciting Investigational Therapy for MDS

Richard K. Shadduck, MD
Vice Chairman, Department of Human Oncology, Allegheny General Hospital
Deputy Director, West Penn Allegheny Health System Oncology Program

Enrollment is on-going for a Phase III clinical trial of the safety and efficacy of thalidomide (Thalomid®) for the treatment of anemia associated with myelodysplastic syndromes (MDS). Thalidomide, you say? That's right, thalidomide may be rising from the ashes of its tragic youth, with its safety profile now well understood and with exciting early results for treating MDS. Indeed, thalidomide is beginning its ascent towards being an approved treatment option for MDS patients.

The Daunting Old News
Beginning in 1956 in Europe, thalidomide was used as a sedative for treatment of anxiety and insomnia as well as a treatment for nausea and vomiting associated with pregnancy. Within a few short years following its introduction, this drug was known to cause severe birth defects and death of the unborn when administered to pregnant women. In the United States, thalidomide had not been approved for clinical use but the unanticipated effects on the unborn was a stimulus for improved testing of fetotoxic and developmental effects of drugs.

The Current Indicated Use
During its early years, thalidomide was observed to successfully treat the painful skin nodules of erythema nodosum leprosum (ENL), a complication of leprosy. These nodules form as small blood vessels become blocked and, if untreated, ultimately lead to loss of feeling and paralysis. Because of the need for treatment and maintenance therapy of these lesions, thalidomide capsules received government approval in 1998 for these limited uses; these are the only uses currently approved for thalidomide. Concurrent with the approvals for treatment of ENL, a System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) was developed and approved by the Food and Drug Administration.

Managing Side Effects
S.T.E.P.S. is a restricted distribution system which requires strict adherence to a well-developed education and safety program. The program includes initial and scheduled pregnancy testing (when applicable), contraception counseling, patient and physician registration, and patient and physician phone surveys at the time of each new prescription. Only registered physicians and pharmacists can prescribe and dispense thalidomide to registered patients and each prescription is limited to a one-month supply. While this education and safety program is unique and may seem cumbersome, S.T.E.P.S. quickly becomes a familiar task to the patient and prescriber. Most importantly, compliance with S.T.E.P.S. is essential for prevention of birth defects.

(continued on page 2)
In contrast to the effects on the unborn, side effects experienced by the patient are dose-dependent and, for the most part, are reversible when treatment with thalidomide is discontinued. These effects include drowsiness, skin rashes, decreased white cell counts, sudden dizziness upon standing, constipation, and swelling of the lower extremities. The exceptions to reversibility may include peripheral neuropathy which begins as numbness and tingling of the toes and fingers and, rarely, a potentially fatal skin disorder known as Stevens-Johnson syndrome.

**Broad Uses and Activity**

Thalidomide has potential uses in inflammatory and autoimmune disorders and in various forms of cancer. Disorders include rheumatoid arthritis, lupus, inflammatory bowel disease, macular degeneration, Behcet disease, Crohn disease, graft-vs-host disease, and cachexia (weight loss and wasting) and painful lesions associated with AIDS. Investigations are ongoing for the benefit of thalidomide in treating various types of cancers as well as for treating MDS. Certainly, thalidomide has proven effective in treating refractory multiple myeloma.1-3

The broad scope of activity may reflect complexity in the mechanism(s) of action. One possible mechanism is down-regulation of the cytokine TNF-α, a protein (alternatively known as cachectin) which normally is found at very low levels. When overproduced, TNF-α causes inflammatory responses and premature cell death (apoptosis). Thalidomide inhibits production of TNF-α and may also affect the levels of other cytokines, such as transforming growth factor beta (TGF-β), and growth factors which regulate apoptosis.4-8

A second mechanism by which thalidomide may effectively treat cancers is through anti-angiogenesis. Angiogenesis is the growth of new blood vessels and is a necessary function of normal body development and repair. Growth of new blood vessels is also a fundamental need for expansion of tumors. Thalidomide has been shown to slow the development of new blood vessels by inhibiting vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).9-10

Finally, thalidomide is known to also have immune-modulating activity.11-15 For example, expression of cell adhesion molecules on endothelial cells is suppressed by thalidomide.16 Indeed, if changes in types of immune cells and their frequency is a mechanism of action of thalidomide, this drug may differ considerably from current cancer drugs, most of which exert a cytotoxic effect on immune cells.

**Utility for Treating MDS**

In MDS, overproduction of TNF-α increases apoptosis of bone marrow cells, with apoptotic cells occurring more frequently in early-stage MDS.17-18 Recent research has also shown that small blood vessels located in the bone marrow may also be found at increased density in MDS and AML patients;19-20 this form of angiogenesis may benefit survival of the malignant cells and, as a result, further increase the production of cytokines.19-22 Thus, both the down-regulation of TNF-α overproduction and inhibition of growth factors promoting angiogenesis are possible mechanisms by which thalidomide exerts therapeutic activity in MDS. However, clinical evidence supporting these mechanisms of action remains elusive,23-24 clearly showing further study is needed to elucidate the activity of thalidomide in MDS.

Clinical trials of thalidomide for treatment of MDS have been limited in number but the results have been impressive for some patients. Within several weeks to months of initiating treatment, hemoglobin levels have increased in many treated patients, to the point that a subset of responders became transfusion independent. In a study of 83 patients where 51 were evaluable, 21 (41%) of the patients treated with...
thalidomide experienced partial remission (mostly patients with early-stage MDS) with eight achieving transfusion independence. Platelet counts also increased in some patients. In another study, where eight of nine patients were evaluable, six responded to thalidomide with three of these becoming transfusion independent and two having resolved neutropenias. Hematologic improvements have been noted in some late-stage patients who had previously been in remission but otherwise benefited for patients with poor-prognosis MDS generally have been less frequent. Yet, in a recent study three of five patients initially classified as RAEB-T showed partial remissions and one RAEB-T patient and one of three CMML patients experienced major hematologic improvement, with all five of these responders becoming platelet and transfusion independent. (It is important to note that the other 2 CMML patients experienced progressive MDS.) Finally, for a group of 30 patients classified with early-stage MDS, ten responded (increases in hemoglobin and platelet count) to thalidomide with eight having major responses. Six of these responders became transfusion independent and responses were maintained for more than one year in four of these patients. Thus, while more clinical trials and much more study are needed, thalidomide has the potential of providing excellent therapeutic activity for many MDS patients. The challenge remains to determine which patients will most likely benefit from thalidomide treatment.

Perhaps thalidomide will rise again but this time will rise as a carefully managed tool for hematologic improvement for MDS patients. Also on the horizon with thalidomide are two of its analogues: Revimid and CC1088. These agents, which are in Phase II clinical trials, may prove to have enhanced safety and greater efficacy.

For further information on the thalidomide, Revimid, and CC1088 trials, contact Dr. Robert Knight, Director of Medical Development for Celgene Corporation, at 732-805-3749.

*Celgene Corporation

References


---

**Erik Johnson Memorial**

A memorial fund has been established by the Myelodysplastic Syndromes Foundation in the name of Erik Johnson. Contributions may be sent to the Foundation with a notation designating the Erik Johnson Memorial Fund.

**MDS Patient Registry**

Pharmacia generously provided an unrestricted grant to help support the Myelodysplastic Syndromes Foundation’s Patient Registry. The Foundation gratefully acknowledges this support and looks forward to building the Patient Registry with our Centers of Excellence. The Patient Registry will help further research into the treatment of MDS.

**MDS RESOURCES**

**The Myelodysplastic Syndromes Pathobiology and Clinical Management**

(Book and Clinical Oncology Series/27)

Edited by:

**John M. Bennett**

James P. Wilmot Cancer Center of the University of Rochester, New York, U.S.A.

May 2002/528 pp., illus.

ISBN: 0-8247-0782-6/$165.00
When ordering, use code PAO50203

This reference provides a comprehensive overview of the latest research detailing the etiology, epidemiology, treatment, and detection of myelodysplastic syndromes (MDS)—identifying effective therapeutic regimens, adverse environmental and genetic factors, and efficient modalities of supportive care that improve patient survival and enhance quality of life.

---

**Celgene**

Innovating Life™

Celgene has provided the MDS Foundation with unrestricted educational grants to support the Foundation’s work.
7th International Symposium on Myelodysplastic Syndromes

May 15–18, 2003
Paris, France

SCIENTIFIC TOPICS
- Classification
- Epidemiology
- Cytogenetics and molecular genetics
- Apoptosis
- Other biological factors
- Treatment
- Supportive care and quality of life

ORGANIZING COMMITTEE
Pierre Fenaux, President
Francois Dreyfus, Vice-President
Nicole Casadevall, Vice-President
Jean-Henri Bourhis
Christine Chomienne
Salem Chouaib
Florence Cymbalista
Herve Dombret
Jean Feuillard
Claud Gardin
Agnes Guerci
Bruno Quesnel
Sophie Raynaud
Vincent Ribrag
Christian Rose
Michel Tulliez
Ali Turhan
Eric Wattel

SCIENTIFIC COMMITTEE
John Bennett
David Bowen
Mario Cazzola
Theo de Witte
Elihu Estey
Georges Flandrin
Michaela Fontenay-Roupie
Arnold Ganser
Norbert Gatterman
Peter Greenberg
Terry Hamblin
Eva Hellstrom-Lindberg
Philip Koeffler
Alan List
Moshe Mittleman
Ghulam Mufti
Charlotte Niemeyer
Jens Pedersen-Bjergaard
Claude Preudhomme
Azra Raza
Guillermo Sanz
Kevin Shannon
Mary Thomas
Gregor Verhoeff
Yataro Yoshida
Neal Young

IMPORTANT INFORMATION
- Second announcement and call for papers: October 2002
- Deadline for abstract submission: February 2003

For further information please contact:
Symposium Secretariat
Check up Service
16, Avenue de General Faidherbe
BP 42 - 94732 Nogent sur Marne cedex - France
Tel: 33 1 48 77 01 13
Fax: 33 1 48 77 08 63
E-mail: webmaster@checkup-service.com

Scientific Secretariat:
Pierre Fenaux/Mrs. Myriam Cambie
Service des Maladies du Sang
CHU, 1 place de Verdon - 59037 LILLE - France
Tel: 33 3 20 44 57 13
Fax: 33 3 20 44 47 08
E-mail: mcambie@oncospace.com
pfenaux@chru-lille.fr

Symposium Website:
www.gfmgroup.org/myelo2002
www.checkup-service.com

Patient Referrals

Myelodysplastic syndromes can be difficult to diagnose and treat. It is important for both patients and their families to know that optimal treatment is available and that quality of life can be enhanced.

If you would like information about treatment options, research, or quality of life, we would be glad to help. The Foundation offers a variety of patient services, including referrals to MDS Centers of Excellence.

Please contact us at:
1-800-MDS-0839 (phone)
or 609-298-0590 (fax).
Outside the US please call 609-298-1035.
You can also visit our Web site at
MDS Centers of Excellence

Would you like your treatment center to become part of the referral system for MDS patients and be designated as a Center of Excellence? To be recognized as a Center of Excellence, an institution must have the following:

- An established university (or equivalent) program
- Recognized morphologic expertise in MDS
- Available cytogenetics and/or molecular genetics
- Ongoing research, including Institutional Review Board–approved clinical trials
- Documentation of peer-reviewed publications in the field
- The ability and intention to register patients in the MDS International Registry database

Please contact the Foundation for further information and an application form for your center.

The following centers have qualified as MDS Centers of Excellence:

**UNITED STATES**

Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
Esteban Abella, MD

The Cancer Center of Hackensack
University Medical Center
Hackensack, New Jersey
Stuart Goldberg, MD

Cedars-Sinai Medical Center
UCLA School of Medicine
Los Angeles, California
H. Philip Koefler, MD

City of Hope National Medical Center
Duarte, California
Stephen J. Forman, MD

Dana-Farber Cancer Institute
Boston, Massachusetts
Richard M. Stone, MD

Cleveland Clinic Foundation
Tausig Cancer Center
Cleveland, Ohio
Jaroslaw Maciejewski, MD

Duke University
Duke University Medical Center
Durham, North Carolina
Carlos M. deCastro, MD

Indiana University
Indiana University Medical Center
Indianapolis, Indiana
Larry Cripe, MD

Johns Hopkins Oncology Center
Johns Hopkins Institutions
Baltimore, Maryland
Steven D. Gore, MD

Mayo Clinic
Rochester, Minnesota
Louis Leventhal, MD

MCP Hahnemann University
Philadelphia, Pennsylvania
Emmanuel C. Besa, MD

Medical College of Wisconsin
Bone Marrow Transplant Program
Milwaukee, Wisconsin
David H. Vesole, MD, PhD, FACP

Memorial Sloan-Kettering Cancer Center
New York, New York
David T. Bowen, MD

University of Chicago
University of Chicago Medical Center
Chicago, Illinois
Richard A. Larson, MD

University of Connecticut
University of Connecticut Health Center
Farmington, Connecticut
Peter Tulasichka, MD

University of Nebraska
University of Nebraska Medical Center
Omaha, Nebraska
Julie Voce, MD

University of Pennsylvania
University of Pennsylvania Health System
Philadelphia, Pennsylvania
Selina Lugert, MD

University of Rochester
University of Rochester Medical Center
Rochester, New York
John M. Bennett, MD

University of South Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Hussain Sabat, MD, PhD

University of Texas
MD Anderson Cancer Center
Houston, Texas
Elhui E. Estey, MD

Washington University School of Medicine
Barnard Cancer Center
St. Louis, Missouri
John F. DiPersio, MD, PhD

Well Medical College of Cornell University
New York Presbyterian Hospital
New York, New York
Eric U. Feldman, MD

The Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania
Richard K. Shadduck, MD

William Beaumont Hospital Cancer Center
Royal Oak, MI
Ishmael Jayesmi, MD

**OUTSIDE THE UNITED STATES**

A.C. Camargo Hospital–Cancer Center
Sao Paulo, Brazil
Lucio Fernando Lopes, MD, PhD

Academic Hospital
Free University Amsterdam
Amsterdam, The Netherlands
G.J. Ossenkoppele, MD, PhD

Athenas University, Evangelismos Hospital
Athens, Greece
Theodorakis Economopoulos, MD

Casa Sollievo Della Sofferenza Hospital
S. Giovanni Rotondo Italy
Pellino Musto, MD

Hannover Medical School
Medizinische Hochschule Hannover
Hannover, Germany
Prof. Dr. Arnold Garser

Heinrich-Heine University Düsseldorf
University Hospital
Düsseldorf, Germany
Ulrich Germing, MD

Hôpital Saint Louis
University Paris VII
Paris, France
Prof. Christine Chomienne

Hospital Universitario de Salamanca
Salamanca, Spain
Prof. Jesu S. F. San Miguel

Hospital Universitario La Fe Valencia, Spain
Miguel A. Sanz, MD, PhD

Jagiellonian University
Collegium Medicum
Krakow, Poland

Johann Wolfgang Goethe University Frankfurt Main, Germany
Wolf-Karsten Hofmann, MD

Karolinska Institute
Huddinge University Hospital
Stockholm, Sweden
Eva Hellström-Lindberg, MD, PhD

King Chulalongkorn Memorial Hospital
Pathumwan, Bangkok, Thailand
Tarin Intraungtornichai, MD

King’s College Hospital
Guy’s Kings Thomas School of Medicine
London, England
Prof. Ghulam J. Multi

Kyoto University Hospital
Kyoto, Japan
Takashi Uchiyama, MD

Ludwig Maximilians University Munich, Germany
Torsten Haferlach, MD

Nagasaki University Hospital
School of Medicine
Atomic Bomb Disease Institute
Nagasaki City, Japan
Prof. Masao Tomonaga

Odense University Hospital
The University of Southern Denmark
Odense, Denmark
Gitte Birk Kærndrup, MD

Patras University Hospital
Patras, Greece
Nicholas Z. Zoubos, MD

Peter MacCallum Cancer Institute
University of Melbourne
East Melbourne, Victoria, Australia
John F. Seymour, MD

Rabin Medical Center–Hasharon Hospital
Tel Aviv University–Sackler School of Medicine
Petah-Tikva, Israel

Salzina Medical School Hospital
Morohongo, Iruma, Japan
Akira Matsumoto, MD

Services D’Hematologie Hôpital Cochin
University Paris V Service
Paris, France
Prof. Pierre Feinax

St. Johanes Hospital
Heinrich-Heine University Duisburg, Germany
Carlo Aul, MD, PhD

The Royal Bournemouh Hospital
Bournemouth, UK
Prof. Terry J. Hamblin

Tokyo Medical College
Tokyo, Japan
Kazuma Ohyashiki, MD

University of Aarhus
The University Hospital Aarhus
Aarhus, Denmark
Professor Johan Lang Nielsen

University of Athens
Laikon Hospital
Athens, Greece
Nora Viniciu, MD

University of Cape Town
Groote Schuur Hospital
Cape Town, Cape South Africa
Nicola Novik, MD, PhD

University of Dundee Medical School
Dundee Teaching Hospital
Dundee, Scotland
David T. Bowen, MD

University of Florence
Azienda DSP Careggi Florence, Italy
Alberto Grossi, MD

University of Freiburg Medical Center
Freiburg, Germany
Michael Luebbert, MD

University Hospital of Innsbruck
Innsbruck, Austria
Prim. Univ. Prof. Dr. Franz Schmidl

University of Nijmegen
University Hospital St. Radboud
Nijmegen, The Netherlands
Theo J.M. deWitte, MD, PhD

University of Tasmania
Royal Hobart Hospital
Hobart, Tasmania, Australia
Prof. Raymond M. Lowenthal, MD, FRCP, FRACP

University of Toronto
Hospital for Sick Children
Toronto, Ontario, Canada
Yigal Droz, MD

University Tor Vergata
Ospedale S. Eugenio
Roma, Italy
Sergio Amadoni, MD

University of Vienna
Vienna, Austria
Peter Valent, MD
Patient Advocacy Groups Are Being Established by the MDS Foundation

The MDS Foundation has been working to develop a strategy for setting up patient groups nationwide. We have now completed this process and would like to have your help.

These volunteers are providing local support to MDS patients and their families, developing new information for patients, and planning fund raising programs to support these activities.

Any member of the Foundation, patients, friends and family members are invited to join with us to move these projects forward.

Please contact the Patient Liaison:

800-MDS-0839 to volunteer.

Your help is needed!!

Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with MDS

Jeffrey J. Molldrem, MD; Eric Leifer, PhD; Erkut Baheci, MD; Yogen Saunthararajah, MD; Mary Rivera, RN; Cynthia Dunbar, MD; Johnson Liu, MD; Riiotoro Nakamura, MD; Neal S. Young, MD; and A. John Barrett, MD

Background: Almost half of the deaths that result from myelodysplastic syndromes are due to cytopenia associated with bone marrow failure. Treatment is mostly supportive care.

Objective: To determine whether treatment with antithymocyte globulin improves cytopenia and reverses dependence on red blood cell transfusions in patients with myelodysplastic syndromes.


Setting: Tertiary referral center.

Patients: 61 Patients with myelodysplastic syndromes.

Intervention: Antithymocyte globulin, 40 mg/kg of body weight, given daily for 4 days.

Measurements: Evaluation of bone marrow, blood counts, transfusions, progression, and survival for a median of 30 months (range, 1 to 88 months).

Results: Within 8 months of treatment, 21 of 61 patients (34%) no longer required red blood cell transfusions. This independence from transfusions was maintained in 17 responders (81%) for a median of 36 months (range, 3 to 72 months). Ten of 21 patients (47.5%) with severe thrombocytopenia had sustained platelet count increases, and 6 of 11 patients (55%) with severe neutropenia had sustained neutrophil counts of greater than $1 \times 10^9$ cells/L. Characteristics favorable for response were younger patient age ($P=0.005$) and lower platelet counts ($P=0.038$). One of the 21 responders (5%) and 22 of the 40 nonresponders (55%) died before the end of the study ($P=0.008$). One of the 21 responders (5%) and 13 of the 40 nonresponders (33%) had disease progression ($P=0.086$).

Conclusions: Although this study was a nonrandomized, single-treatment study, 34% of patients treated with antithymocyte globulin became transfusion independent. Response was associated with a statistically significant longer survival and an almost significant decreased time to disease progression. Treatment with antithymocyte globulin did not seem to be detrimental because historical overall median survival times were similar to those of nonresponders.

International Clinical Trials: An Update

The following trials are current as of the date of this newsletter. We will update the list in The MDS News each quarter. If you are a treating physician who would benefit from any such study, you may want to contact the appropriate institution. If you are an MDS patient, you may wish to discuss a trial with your primary treating physician to see if you qualify as a candidate.

Clinical trials study new interventions (drugs or procedures) to evaluate their safety and effectiveness in humans. Trials follow a careful set of steps, allowing for the systematic gathering of information to answer questions and confirm hypotheses that were formed earlier, in either laboratory experiments or preliminary trials.

A clinical trial falls into one of four phases:

**Phase I.** This is the first time a drug is used in humans. The trial is designed to determine dosage, route of administration (oral, intravenous, or by injection), and schedule of administration (how many times a day or week). In this phase researchers also begin to determine the drug’s safety. The phase I trial is normally conducted in healthy adults and enrolls only a small number of people.

**Phase II.** Patients with the disease receive the drug at dose levels determined in the earlier phase. The phase II trial begins to determine the effectiveness of the drug and provides more information about its safety.

**Phase III.** The drug is tested alone or against an approved standard drug. The typical phase III trial enrolls a large number of patients. If it is a comparison trial, patients may be randomly assigned to receive either the new drug or the standard intervention.

**Phase IV.** In phase IV the drug, already approved by the FDA and available to the public, undergoes continued evaluation. The phase IV designation is rare.

Some trials—screening studies evaluating supportive care or prevention—are not conducted in phases. In these trials a group following a certain disease combating strategy, such as a detection method, is compared to a control group.

**U.S. Trials**

**NATIONAL CANCER INSTITUTE TRIALS**

**NCI-G00-1899.** Herbert Irving Comprehensive Cancer Center. Phase II study of allogeneic umbilical cord and placental blood transplantation in patients with chronic myeloid leukemia, acute leukemia, lymphoma, myeloma, myelodysplasia, aplastic anemia, Fanconi’s Anemia, histiocytosis, hereditary immunodeficiency, or storage disorder. Contact: David G. Savage, MD. Phone: 212-305-9783.

**NCI-G97-1354.** Ireland Cancer Center at Case Western Reserve University. Phase II study of allogeneic peripheral blood progenitor cell transplantation using histocompatible sibling-matched donor cells after high-dose busulfan/cyclophosphamide for hematologic malignancy. Contact: H. Lazarus, MD. Phone: 216-844-3629.

**NCI-G98-1429.** Ireland Cancer Center at Case Western Reserve University/Ireland Cancer Center. Phase II pilot study of unrelated umbilical cord blood transplantation in patients with high-risk hematologic malignancies. Contact: M. Laughlin, MD. Phone: 216-844-8609.

**NCI-G98-1431.** Case Western Reserve University/Ireland Cancer Center. Phase II study of unrelated umbilical cord blood transplantation for severe aplastic anemia, inborn errors in metabolism, or inherited hematologic stem cell disorders. Contact: M. Laughlin, MD. Phone: 216-844-8609.


**NCI-G99-1573.** Cancer Institute of New Jersey. Phase I study of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with relapsed or refractory hematologic malignancies or bone marrow disorders. Contact: R. Strain, MD. Phone: 908-235-6777.

**NCI-G99-1617.** Duke University. Phase II study of allogeneic mixed chimerism peripheral blood stem cell transplantation utilizing in vivo and in vitro monoclonal antibody CD52 (campath-1H) in patients with high risks hematologic malignancies or diseases. Contact: D.A. Rizzi, MD. Phone: 919-668-1000.


**NCI-G00-1759.** H. Lee Moffitt Cancer Center and Research Institute. Phase II study of allogeneic bone marrow transplantation in patients with hematologic malignancies. Contact: Steven C. Goldstein, MD. Phone: 813-979-7202.

**NCI-G00-1793.** Fred Hutchinson Cancer Research Center. Phase II study of anti-thymocyte globulin and tumor necrosis factor receptor IgG chimera in patients with MDS. Contact: H. Joachim Deeg, MD. Phone: 206-667-5985.

**NCI-G00-1815.** Memorial Sloan-Kettering Cancer Center. Phase I study of Yttrium Y 90 humanized monoclonal antibody M195 and etoposide followed by autologous peripheral blood stem cell transplantation in patients with advanced MDS or refractory leukemia. Contact: Peter Maslak, MD. Phone: 212-639-5518.


**NCI-G00-1868.** Ireland Cancer Center. Phase II study of non-myeloablative conditioning using fludarabine, cyclophosphamide, and anti-thymocyte globulin, followed by allogeneic peripheral blood stem cell transplantation in patients with high risk hematologic malignancies or severe anaplastic anemia. Contact: Mary J. Laughlin, MD. Phone: 216-844-8609.

**NCI-G00-1891.** Herbert Irving Comprehensive Cancer Center. Phase II study of allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancy. Contact: David G. Savage, MD. Phone: 212-305-9783.

**NCI-G00-1897.** Herbert Irving Comprehensive Cancer Center. Phase II study of fludarabine and melphalan followed by allogeneic
or syngeneic bone marrow or peripheral blood stem cell transplantation in patients with hematologic malignancies or genetic disorders. Contact: David G. Savage, MD. Phone: 212-305-9783.

NCI-G00-1889. Memorial Sloan-Kettering Cancer Center. Phase III randomized study of caspofungin acetate versus amphotericin B liposomal in patients with persistent fever and neutropenia following treatment for cancer. Contact: Kent Sepkowitz, MD. Phone: 212-639-2441.


NCI-G01-1971. Jonsson Comprehensive Cancer Center, UCLA. Phase II study of arsenic trioxide in patients with MDS. Contact: Gary Jonsson Comprehensive Cancer Center, UCLA. Phone: 310-825-7768.


NCI-H01-0070. Memorial Sloan-Kettering Cancer Center. Phase II study of busulfan and melphalan followed by allogeneic bone marrow transplantation in patients with advanced or high-risk hematologic malignancy. Contact: Trudy Small, MD. Phone: 212-639-5965.


NCI-T99-0017. University of Texas–MD Anderson Cancer Center. Phase II/I randomized study of PR1 leukemia peptide vaccine and montanide ISA-51 in patients with chronic myeloid leukemia, AML, or MDS. Contact: Jeffrey J. Mollerd, MD. Phone: 713-792-2933.


NCI-V00-1611. Robert H. Lurie Comprehensive Cancer Center, Northwestern University. Phase II/I randomized study of ex vivo expanded megakaryocytes in patients with breast cancer or hematologic malignancies. Contact: Jane N. Winter, MD. Phone: 312-695-6180.


NCI-38. Stanford University Medical Center. Phase I/I study of R115777 in patients with myeloproliferative disorders. Contact: Peter L. Greenberg, MD. Phone: 650-725-8355.


NCI-2771. Stanford University Medical Center. Phase I/I study of bevacizumab in patients with MDS. Contact: Peter L. Greenberg, MD. Phone: 650-725-8355.


myeloablative, HLA-matched allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Contact: Michael Bishop, MD. Phone: 301-435-2764.

*For more information on NCI trials, contact cancerinfo.cancer.gov/trialsearch.shtml

**PHARMACEUTICAL TRIALS LISTED WITH NCI**

**SMC-101-1020.** SangStat Medical Corporation. An open-label, prospective, stratified, randomized, controlled, multi-center, phase IIb study of Thymoglobin® therapy on transfusion needs of patients with early myelodysplastic syndrome (MDS). Contact: Elizabeth Squiers, MD. Phone: 510-789-4535.

**SUGEN-SU541.** Called for institution. Phase II study of SU5416 in patients with advanced or refractory hematologic malignancies. Contact: Paul Scigalla, MD. Phone: 650-837-3792.

**CHIMERIC-HM01.** Chimeric Therapies Incorporated. Phase II/III randomized study of processed versus unprocessed unrelated bone marrow transplantation in patients with acute or chronic leukemia or myelodysplastic syndrome. Contact: Rosemary Satterlee, RN. Phone: 949-347-9640.

**SUPERGEN-D-0007.** Phase III randomized study of decitabine versus supportive care in patients with advanced myelodysplastic syndrome. Contact: Hussain I. Saba, MD. Phone: 813-972-7582

**Other U.S. Trials**


**Barbara Ann Karmanos Cancer Institute**, 2-2341. A multi center, single arm, open label, phase I clinical trial to evaluate the efficacy and safety of processed hematopoietic stem cell preparation from unrelated or partially matched related donors in patients with poor prognosis hematologic disorders. Contact: Jared Klein, MD. Phone: 313-966-7434.

**Barbara Ann Karmanos Cancer Institute**, 2-2134. A multi center, randomized, single arm, Phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donor (HLA 5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Jared Klein, MD. Phone: 313-966-7434.

**Barbara Ann Karmanos Cancer Institute**, 2-2045. A multi center, open label, randomized, active controlled Phase II/III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Jared Klein, MD. Phone: 313-966-7434.


**Cedars-Sinai Medical Center**, 104864-A/201. Phase III open-label multicenter, randomized, comparative study of topotecan, Ara-C and G-CSF (TAG) VS idarubicin.
advanced myelodysplastic syndrome, acute myelogenous leukemia, chronic myelogenous leukemia in blast crisis and acute lymphoblastic leukemia. Contact: Ilene Galinsky, RN. Phone: 613-632-3902.

**Dana Farber Cancer Institute.** DFCI 99-249. A phase I study of vaccination with lethally irradiated, autologous acute myeloblastic leukemia cells engineered by adenoviral mediated gene transfer to secrete granulocyte macrophage colony stimulating factor in patients with advanced myelodysplasia or acute myelogenous leukemia. Contact: Ilene Galinsky, RN. Phone: 613-632-3902.

**Fred Hutchinson Cancer Research Center.** #1596. Transplantation from related donors for high risk patients with MDS. Conditioning includes a “non-myeloblastic” regimen of fludarabine and 200 cGy of total body irradiation. Patients are evaluated individually for eligibility. Contact: Eric Sievers, MD. Phone: 206-288-1024.


**H. Lee Moffitt Cancer Center and Research Institute.** SMC-101-1020. An open-label, prospective, randomized, controlled, multi-center, phase II study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early myelodysplastic syndrome. Contact: Stuart Goldberg, MD. Phone: 201-996-5849 or Scott D. Rowley, MD. Phone: 204-996-5900.

**Hoosier Oncology Group.** Phase II trial of topotecan, fludarabine, cytosine, arabinoside and G-CSF (TFLAG) induction therapy in patients with poor prognosis AML, MDS and relapsed/refractory ALL. Contact: E. Besa, MD. Phone: 215-842-6980.

**Indiana Blood and Marrow Transplant.** HMO1. A multi-center, open-label, randomized, controlled phase III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Mary Cangany. Phone: 317-783-8510.

**Indiana Blood and Marrow Transplant.** HMO3. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLAS/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Mary Cangany. Phone: 317-783-8510.

**Indiana Blood and Marrow Transplant.** LLC. SMC-101-102. Open-label, prospective, stratified, randomized, controlled, multi-center, phase IIIB clinical trial to evaluate the treatment needs of patients with early myelodysplastic syndrome (MDS). Contact: Stuart Goldberg, MD. Phone: 201-996-5849.

**Indiana Blood and Marrow Transplant.** B3T-MC-JTAH(a). Phase II study of LY335979 plus daunorubicin and cytarabine in subjects with de novo high risk acute myelogenous leukemia or relapsed/refractory acute myelogenous leukemia. Contact: L. Cripe, MD. Phone: 317-274-3545.
Indiana University Medical Center. IU #9907-25. Induction Chemotherapy with the addition of a new MDR inhibitor for patients with RAEB-t or AML that has progressed from a documented phase of MDS. Contact: L. Cripe, MD. Phone: 317-274-3545.

Indiana University School of Medicine. Phase II trial of subcutaneously administered recombinant human interleukin-11 in thrombocytopenic patients with MDS. Contact: L. Cripe, MD. Phone: 317-274-3545.

Indiana University School of Medicine. An Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of the Farnesyl-transferase Inhibitor ZARNESTRA (R1577) in subjects with High-risk Myelodysplastic Syndrome (MDS). Contact: L. Cripe, MD. Phone: 317-274-3545.

Ireland Cancer Center in Cleveland, Ohio. A phase II trial using umbilical cord blood to evaluate the efficacy of transplantation to treat aplastic anemia and myelodysplastic syndromes patients. Contact: Mary Laughlin, MD. Phone: 216-844-8609.


James Graham Brown Cancer Center. HMO5. A multi-center, single-arm, open label, phase I clinical trial to evaluate the efficacy and safety of processed hematopoietic stem cell preparations from unrelated or partially matched related donors in patients with poor prognosis hematologic disorders. Contact: Roger Herzog, MD. Phone: 502-852-8050.

Johns Hopkins Oncology Center. J0051. Phase I trial: GM-CSF and Bryostatin-1 in combination to treat MDS, AML, and other myeloid malignancies. Therapy is designed to enhance differentiation of myeloid progenitors and blasts to improve marrow function and eliminate tumor cell clone. Contact: Douglas Smith, MD. Phone: 410-614-5068.


Karmanos Cancer Institute, Detroit Medical Center. HMO1. A multi-center, open-label, randomized, active controlled phase II/III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Roy Baynes, MD. Phone: 313-966-7021.

Karmanos Cancer Institute, Detroit Medical Center. HMO3. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLA5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Roy Baynes, MD. Phone: 313-966-7021.

Karmanos Cancer Institute, Detroit Medical Center. HMO5. A multi-center, single-arm, open label, phase I clinical trial to evaluate the efficacy and safety of processed hematopoietic stem cell preparations from unrelated or partially matched related donors in patients with poor prognosis hematologic disorders. Contact: Roy Baynes, MD. Phone: 313-966-7021.

KUMC Hematology. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIb study of the impact of thymoglobulin therapy on transfusion needs of patients with early MDS. Contact: Barry Skiene, MD. Phone: 913-588-6077.

LSU Health Sciences Center-Shreveport. HMO1. A multi-center, open-label, randomized, active controlled phase II/III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Barry Weinberger, DO, MPH. Phone: 318-675-5972.

LSU Health Sciences Center-Shreveport. HMO3. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLA5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Barry Weinberger, DO, MPH. Phone: 318-675-5972.

LSU Health Sciences Center-Shreveport. HMO4. A multi-center, non-randomized single-arm, phase I clinical trial to evaluate the safety and efficacy of processed bone marrow from mismatched related donors (HLA3/6 and 4/6) in acute or chronic leukemia patients. Contact: Barry Weinberger, DO, MPH. Phone: 318-675-5972.

LSU Health Sciences Center-Shreveport. HMO5. A multi-center, single-arm, open label, phase I clinical trial to evaluate the efficacy and safety of processed hematopoietic stem cell preparations from unrelated or partially matched related donors in patients with poor prognosis hematologic disorders. Contact: Barry Weinberger, DO, MPH. Phone: 318-675-5972.


MCP Hahneman University. Protocol #00713-01. A randomized study of the safety and efficacy of 2 dose schedules of Gentuzumab Ozogamicin (mylotarg) in patients with intermediate-2 or high risk MDS. Contact: Carolyn Woodland, RN, OCN Phone: 215-842-7553.

MCP Hahneman University. Protocol #00821. A randomized, multi-center, double-blind, placebo controlled trial assessing the safety and efficacy of thalidomide (Thalomid) for the treatment of anemia in red blood cell transfusion dependent patients with myelodysplastic syndromes. Contact: Carolyn Woodland, RN, OCN Phone: 215-842-7553.

MD Anderson Cancer Center. DM01-093. Prospective randomized Phase III study of idarubicin and ara-c versus troxatyl and idarubicin in previously untreated patients 50 years or older with AML, RAEB, or RAEB-t with an unfavorable karyotype. Contact: Francis Giles or Elihu Estey, MD. Phone: 713-792-7305.

MD Anderson Cancer Center. ID00-180. Phase II study of 545416 in patients with refractory acute leukemia, refractory myelodysplasia, Philadelphia negative myeloproliferative disorders, chronic myelogenous leukemia in blastic phase, agranular myeloid metaplasia and multiple myeloma. Contact: Francis Giles. Phone: 713-792-7305.

MD Anderson Cancer Center. ID00-270. Phase II Study of R15777, a farnesyl transferase inhibitor, in refractory hema-tologic cancers. Contact: Hagop Karanian. Phone: 713-792-7305.

MD Anderson Cancer Center. ID01-167. Therapy of Bca-ABL negative myeloproliferative disorders, chronic myelogenous leukemia in blastic phase, phase II trial of topotecan and cytarabine in myelodysplastic syndrome. Contact: Miloslav Beran. Phone: 713-792-7305.
MD Anderson Cancer Center. DM97-151. Phase II study of topotecan, cytarabine and GM-CSF combination in high risk refractory anemia. Contact: Miloslav Beran. Phone: 713-792-7305.

MD Anderson Cancer Center. DM01-033. Pilot trial of cyclooxib on patients with low risk (less than 10% blasts) MDS. Contact: Robert Quackerburgh. Phone: 713-792-7305.

MD Anderson Cancer Center. ID99-059. ATG +/- cyclosporin +/- fludarabine in RA, RARS, RAEB <10% blasts Contact: Jeff Mallaren, MD. Phone: 713-745-4820.

MD Anderson Cancer Center. DM 00-101. Mylotarg +/- IL-II in AML, RAEB, RAEB-t, CMML, >10% blasts in patients 65 years and older with normal cytogenetics. Contact: Elihu Estey, MD. Phone: 713-794-7544.

MD Anderson Cancer Center. DM00-186. Thalidomide in RA, RARS, MDS with low to intermediate risk IPSS. Contact: Deborah Thomas, MD. Phone: 713-745-4616.

MD Anderson Cancer Center. IDP00-269. Reverse transcriptase inhibitors in refractory or relapsed MDS, AML, MPD. Contact: Hagop Kartarjian, MD. Phone: 713-792-7026.


MD Anderson Cancer Center. ID95-124. 9-Nitroctamp-tothecin in MDS, CML, MPD. Contact: Jorge Cortes, MD. Phone: 713-794-5783.

MD Anderson Cancer Center. ID98-152. Idarubicin and Ara-C CI in AML, RAEB, RAEB-t, CMML, with >10% blasts in patients 65 years and older with abnormal cytogenetics. Contact: Elihu Estey, MD. Phone: 713-794-7544.

MD Anderson Cancer Center. HMO1. A multi-center, open-label, randomized, active controlled phase III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Helen Huddleston. Phone: 713-745-1721.

MD Anderson Cancer Center. HMO3. A multi-center, non randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLA5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Helen Huddleston. Phone: 713-745-1721.

Medical City Dallas Hospital-Texas Oncology, PA. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIIB study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: D. Vesole, MD. Phone: 414-805-4646.


Medical College of Wisconsin. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIIB study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: David Vesole, MD. Phone: 414-805-4646.


Memorial Sloan-Kettering Cancer Center. 00-116. A pilot study of FR901228 or Depsipeptide (NSC#630176) for adult patients with advanced hematologic Cancers. Contact: Virginia Klimke, MD. Research Assistant: Rhonda Tang. Phone: 646-227-2194.

Memorial Sloan-Kettering Cancer Center. 01-094. A randomized, open-label, phase III trial of Declaratine (5-AZA-2-Deoxyxycytidine) versus supportive care in adults with advanced stage myelodysplastic syndrome. Contact: Virginia Klimke, MD. Research Assistant: Rhonda Tang. Phone: 646-227-2194.

Memorial Sloan-Kettering Cancer Center. 190. Phase II study of arsenic trioxide in relapsed or refractory, CML. Contact: David Scheinberg, MD. Phone: 212-639-5010.

Mount Sinai Hospital. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multi-center, phase IIb study of Thymoglobulin® therapy on transfusion needs of patients with early myelodysplastic syndrome (MDS). Contact: Steven Fruchtmann, MD. Phone: 212-241-6021.


National Institutes of Health. National Heart Lung and Blood Institute. 00-H-0169. Phase II study of anthymocyte globulin (ATG) and cyclosporine in patients with MDS (RA, RARS, RAEB) who have moderate to severe cytopenias. Contact: Laura B. Wisch, RN. Phone: 301-402-0797.


New York Medical College. A three year evaluation of the overall and leukemia free survival of patients who received Thymoglobulin® therapy for early myelodysplastic syndrome (MDS). Contact: Karen Seiter, MD. Phone: 914-493-8374.

New York Medical College. 0012-2000. (SMC-101-1020.) An open-label, prospective, stratified, randomized, controlled, multi-center,
Phase II study of Thymoglobulin® therapy on transfusion needs of patients with early myelodysplastic syndrome (MDS). Contact: Karen Seiter, MD. Phone: 914-493-8374.


New York Presbyterian Hospital–Columbia Medical Center. 104864-A/201 Study. Phase III open label, randomizes comparative study of topotecan, Ara-C and G-CSF (TAG) vs idarubicin, Ara-C and GCSF (IDAG) in MDS. Over the age of 18 with either: (a) RAEB; (b) RAEB-t; (c) high risk MDS defined by IPSS of 2.0; or (d) AML which has evolved from a pre-existing MDS. Contact: Charles Hesdorffer, MD. Phone: 212-305-4907.

New York Presbyterian Hospital–Columbia Medical Center. Camp 026. Autologous peripheral stem cell harvesting and transplantation for high risk MDS. IPS score greater than 2.0, no allo match, age 18–70. Idarubicin/Ara-C for mobilization followed by BMT with a BU/Cy regimen. Contact: Charles Hesdorffer, MD. Phone: 212-305-4907.


Oklahoma Health Sciences Center. HMO1. A multi-center, open-label, randomized, active controlled phase II clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Boo Bennett. Phone: 405-271-8920.

Oregon Health & Science University Cancer Institute. MOL-00082-L (IRB #6415). Analysis of receptor tyrosine kinase mutations in myelodysplastic/acute myelogenous leukemia (this is a lab study, not a treatment study). Contact: Lea Smith. Phone: 503-494-0896.

Oregon Health & Science University Cancer Institute. HEM-999080-L (IRB #5737). Bone marrow stromal dysfunction, clonal evolution and secondary myelodysplasia (this is a lab study, not a treatment study and requires bone marrow and blood samples). Contact: Cara Laney. Phone: 503-494-8476.

Oregon Health & Science University Cancer Institute. HEM-96123-C (IRB #0602-212). CGG-2961: A phase III study in children with untreated acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). (This is a CGG cooperative group trial.) Contact: Alisa Eicher. Phone: 503-418-5336.

Oregon Health Sciences Center. HMO1. A multi-center, open-label, randomized, active controlled phase II clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Florence Seelig. Phone: 503-494-1553.

Oregon Health Sciences Center. HMO3. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLA5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Mark W. Brunvand, MD. Phone: 303-388-4876.

Rocky Mountain Blood and Marrow Transplant Center. HMO1. A multi-center, open-label, randomized, active controlled phase III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Mark W. Brunvand, MD. Phone: 303-388-4876.

Rocky Mountain Blood and Marrow Transplant Center. HMO3. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLA5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Mark W. Brunvand, MD. Phone: 303-388-4876.

Roswell Park Cancer Institute. DS-01-19. A randomized, open-label, phase III trial of decitabine versus supportive care in adults with advanced stage MDS. Contact: Dr. James Slack. Phone: 716-845-3544.

Roswell Park Cancer Institute. DS-01-07. Phase II multi-center trial of arsenic trioxide in patients with MDS. Contact: Dr. James Slack. Phone: 716-845-3544.

Roswell Park Cancer Institute. DS-01-16. A randomized, multi-center, double-blind, placebo controlled trial assessing the safety and efficacy of thalidomide for the treatment of anemic patients with MDS. Contact: Dr. James Slack. Phone: 716-845-3544.


Rush Cancer Institute. MDS 2002-01: A Phase II study to determine the clinical efficacy of Trisenox (arsenic trioxide) as a single agent in myelodysplastic syndromes followed by combination therapy with thalidomide in non-responders. Contact: Laurie A. Lisak, PA-C. Phone: 312-563-2538.

Rush Cancer Institute. MDS 2000-02. Combination of thalidomide and topotecan in the treatment of patients with high risk MDS. Contact: Laurie A. Lisak, PA-C. Phone: 312-563-2538.


Rush Cancer Institute. MDS 2000-05. A three year evaluation of the overall and leukemic free survival of patients who received thymoglobulin therapy for early MDS. Contact: A. Raza, MD. Phone: 312-455-8474.


Rush Cancer Institute. MDS 2000-10. A pilot study to determine the clinical effects of arsenic trioxide and thalidomide in myelodysplastic syndromes. Contact: Laurie Lisak, PA-C. Phone: 312-563-2538.

Rush Cancer Institute. MDS 2000-11. Pilot study to test the efficacy of InflixaIm (Remicade) in patients with low risk myelodysplastic syndromes. Contact: Laurie Lisak, PA-C. Phone: 312-563-2538.


Rush Cancer Institute. MDS 2002-01: A Phase II study to determine the clinical efficacy of Trisenox (arsenic trioxide) as a single agent in myelodysplastic syndromes followed by combination therapy with thalidomide in non-responders. Contact: Laurie Lisak, PA-C. Phone: 312-563-2538.

Rush Cancer Institute. MDS 2002-02: A0401002, A Dose Escalation (Phase I) and Phase II Study of AG013736 in Patients With Secondary Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). Contact: Laurie A. Lisak, PA-C. Phone: 312-563-2538.

Rush Cancer Institute. MDS 2002-03: An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of the Farnesytransferase Inhibitor ZARNESTRA (R115777) in Subjects with High-Risk Myelodysplastic Syndrome (MDS). Contact: Laurie A. Lisak, PA-C. Phone: 312-563-2538.


Rush Cancer Institute. MDS 501-001: A pilot study to test the efficacy of CC-5013 in patients with myelodysplastic syndromes. Contact: Laurie A. Lisak, PA-C. Phone: 312-563-2538.


Saint Louis University School of Medicine. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIb study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: John M. Richart, MD. Phone: 314-557-8854.


Salick Health Care, Inc. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIb study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: Sanford Kempin, MD. Phone: 212-604-6011.

Shands Hospital at the University of Florida. HMO1. A multi-center, open-label, randomized, active controlled phase I/II clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: John R. Wingard, MD. Phone: 352-395-0062.

Shands Hospital at the University of Florida. HMO3. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLA5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Frederick Le Maistre, MD. Phone: 210-575-3801.

Shands Hospital at the University of Florida. HMO4. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the safety and efficacy of processed bone marrow from mismatched related donors (HLA3/6 and 4/6) in acute or chronic leukemia patients. Contact: Frederick Le Maistre, MD. Phone: 210-575-3801.

Stanford University Medical Center. CTEP #2771. Safety and efficacy of Bevacizumab: Humanized monoclonal anti-VEGF antibody therapy for myelodysplastic syndrome. Contact: Peter Greenberg, MD or Kathy Dugan, RN. Phone: 650-723-8594.

Stanford University Medical Center. CTEP #38. Phase II of study of Farreys/transferase inhibitor R115777 in patients with myeloproliferative disorders. Contact: Peter Greenberg, MD or Kathy Dugan, RN. Phone: 650-723-8594.

Southwest Oncology Group. SWOG-S9920. Phase II randomized study of total body irradiation (TBI) plus busulfan versus TBI plus cyclophosphamide followed by allogeneic peripheral blood stem cell transplantation in patients with advanced MDS or MDS related AML. Contact: Charles A. Coltman, Jr., MD. Phone: 210-616-5580.


Texas Cancer Center. SMC-101-1020. Phase IIb study of thymoglobulin in transfusion dependent patients with RA or RAEB. Contact: Craig Rosenfeld, MD. Phone: 972-566-7790.

Texas Transplant Institute. HMO1. A multi-center, open-label, randomized, active controlled phase I/III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Frederick Le Maistre, MD. Phone: 210-575-3801.

Texas Transplant Institute. HMO3. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLA5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Frederick Le Maistre, MD. Phone: 210-575-3801.

Texas Transplant Institute. HMO4. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the safety and efficacy of processed bone marrow from mismatched related donors (HLA3/6 and 4/6) in acute or chronic leukemia patients. Contact: Frederick Le Maistre, MD. Phone: 210-575-3801.

Tulane University Health Science Center. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIb study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: Hanah Safah, MD. Phone: 504-585-6070.

University of Arizona Cancer Center. A randomized, double-blind, phase II study of the matrix metalloprotease inhibitor prinomastat in patients having MDS. Contact: Alan List, MD. Phone: 520-626-2340.

University of Arizona Cancer Center. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. Contact: Alan List, MD. Phone: 520-626-2340.

University of Arizona Cancer Center. A randomized study of the safety and efficacy of two does schedules of gemtuzumab ozogamicin in patients with Intermediate-2 or high risk myelodysplastic syndromes. Contact: Alan List, MD. Phone: 520-626-2340.

University of Arizona Cancer Center. A phase II study of continuous oral administration of SCH 66336 in patients with advanced myelodysplastic syndromes. Contact: Alan List, MD. Phone: 520-626-2340.
University of Arizona Cancer Center. A Phase II open label study of the efficacy of CC-5013 (Revimid®) treatment for patients with myelodysplastic syndrome. Contact: Alan List, MD. Phone: 520-626-2340.

University of Arizona Cancer Center. Safety and efficacy trial of bevacizumab: anti-VEGF humanized monoclonal antibody (NSC 704865) therapy for myelodysplastic syndrome. Contact: Alan List, MD. Phone: 520-626-2340.


University of Arizona Cancer Center. A Phase II Open Label Study of the Efficacy Of CC-5013 (Revimid®) Treatment for Patients with MDS (Celgene HSC 01-164) Contact: Alan List, MD. Phone: 520-626-2340.

University of Arizona Cancer Center. A Phase I/II Study of Continuous Oral Administration of SCH 66336 in Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, Acute Lymphoblastic Leukemia (Schering Plough, HSC 01-132) Contact: Alan List, MD. Phone: 520-626-2340.

University of Arizona Cancer Center. Safety and Efficacy Trial of bevacizumab: anti-VEGF humanized monoclonal antibody therapy for MDS (HSC # 02-11) Contact: Alan List, MD. Phone: 520-626-2340.


University of California, San Diego Cancer Center. HM01. A multi-center, open-label, randomized, active controlled phase II/III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Asad Bashey, MD, PhD. Phone: 858-657-6790.


University of Florida. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIB study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: Katarzyna Finiewicz, MD. Phone: 352-392-4925.


University of Iowa Hospitals and Clinics. SMC-101-102. Open-label, prospective, stratified, randomized, controlled, multi-center, Phase IIb study of the impact of Thymoglobulin® therapy on the transfusion needs of patients with early myelodysplastic syndrome (MDS). Contact: Raymond J. Hohl, MD. Phone: 319-356-8110.

University of Kansas Medical Center. SMC-101-102. Open-label, prospective, stratified, randomized, controlled, multi-center, Phase IIb study of the impact of Thymoglobulin® therapy on the transfusion needs of patients with early myelodysplastic syndrome (MDS). Contact: Barry Skikne, MD. Phone: 913-588-6077.

University of Maryland Greenebaum Cancer Center. UMGCC 0050. Phase I trial of oral medication MS-275, given for 28 days to reinstate the expression of genes which cause cells to mature. Contact: Judith E. Karp, MD. Phone: 410-328-7394.

University of Maryland Greenebaum Cancer Center. UMGCC 0001. The use of topotecan, Ara-C, and mitoxantrone TST in aggressive MDS. Contact: Judith E. Karp, MD. Phone: 410-328-7394.

University of Massachusetts. A pilot study on the effectiveness of Thalomid® Thalidomide combined with Procrit® for the treatment of anemia in patients with low and intermediate risk (IPSS score less than 1.5) in myelodysplastic syndromes. Contact: Laszlo Lab, MD. Phone: 50583-363-9233 ext. 72373.

University of Miami. SMC-101-102. Open-label, prospective, stratified, randomized, controlled, multi-center, Phase IIb study of the impact of Thymoglobulin® therapy on the transfusion needs of patients with early myelodysplastic syndrome (MDS). Contact: Mark Goodman, MD. Phone: 305-243-4995.

University of Michigan Comprehensive Cancer Center. UMCC 0068. A randomized study of the safety and efficacy of two dose schedules of gemtuzumab ozogamicin (Mylotarg) in patients with intermediate-2 or high risk MDS. Contact: Harry P. Erba, MD, PhD. Phone: 734-647-8921.

University of Michigan Medical Center. UMCC 9906. Combination of azacytidine and amifostine in the treatment of adults with MDS. Contact: Harry P. Erba, MD. Phone: 734-647-8921.

University of Michigan Medical Center. Clinical treatment via bone marrow transplant for hematologic malignancies. Contact: Dr. Harry D. Erba, MD. Phone: 734-647-8921.

University of Nebraska Medical Center. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIB study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: James Foran, MD. Phone: 402-559-6120.

University of Nebraska Medical Center. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIB study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: James Foran, MD. Phone: 402-559-6120.

University of Rochester. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIB study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: Camille N. Abboud, MD. Phone: 716-275-2881.
University of Rochester. HMO1. A multi-center, open-label, randomized, active controlled phase I/II clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Sharon Swift. Phone: 585-275-2262.

University of Rochester. HMO3. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLA5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Sharon Swift. Phone: 585-275-2262.


University of Rochester Cancer Center. IB400. A randomized study of the safety and efficacy of two dose schedules of gemtuzumab ozogamicin in patients with intermediate-2 or high risk MDS. Contact: Jane Pantoja. Phone: 585-275-4915.

University of Texas Health Science Center. IRB #978-5008-302. Sequential antithymocyte globulin (ATG) and amifostine for the treatment of MDS. ATG is given as an intravenous infusion in the hospital over 4 days. Skin testing for sensitivity to ATG performed prior to the first dose. Amifostine is given as an IV push. Contact: J. Anderson, MD. Phone: 210-567-4848.

University of Washington, Seattle Cancer Care Alliance. 95-04570-A 05. Determining safety, tolerance, and maximum tolerated dose of SC Interleukin-2 in MDS patients. Contact: John A. Thompson, MD. Phone: 206-288-2041.


VCUHS MCV Hospitals, Virginia. Bone Marrow Transplant Program. HMO1. A multi-center, open-label, randomized, active controlled phase I/III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Kathy Candler. Phone: 804-828-4360.

VCUHS MCV Hospitals, Virginia. Bone Marrow Transplant Program. HMO3. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLA5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Sharon Swift. Phone contact: Kathy Candler. Phone: 804-828-4360.

VCUHS MCV Hospitals, Virginia. Bone Marrow Transplant Program. HMO3. A multi-center, single-arm, open label, phase I clinical trial to evaluate the efficacy and safety of processed hematopoietic stem cell preparations from unrelated or partially matched related donors in patients with poor prognosis hematologic disorders. Contact: Kathy Candler. Phone: 804-828-4360.

Wake Forest University. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIb study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: Kenneth Zamkoff, MD. Phone: 336-716-7972.

Washington Cancer Institute. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIb study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: Joseph P. Catlett, MD. Phone: 202-877-4635.

Washington University in St. Louis. 95-0384. Washington University School of Medicine. A phase II study to evaluate the tumor response rate and toxicity of granulocyte-colony stimulating factor (G-CSF) primed donor leukocyte infusion administered to patients with relapsed hematologic malignancy occurring after allogeneic bone marrow or peripheral blood stem cell transplant. Contact: D.R. Adkins, MD. Phone: 314-454-8490.


Washington University (Wohl Hospital) in St. Louis. SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIb study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: John F. DiPterso, MD, PhD. Phone: 314-454-8313.


Westchester County Medical Center, NYC Medical College. HMO1. A multi-center, open-label, randomized, active controlled phase I/III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia. Contact: Karen Seiter, MD. Phone: 914-285-8374.

Westchester County Medical Center, NYC Medical College. HMO3. A multi-center, non-randomized single arm, phase I clinical trial to evaluate the efficacy and safety of processed bone marrow from mismatched unrelated donors (HLA5/6) in acute or chronic leukemia patients who are older than 35 years of age. Contact: Karen Seiter, MD. Phone: 914-285-8374.

Westchester County Medical Center, NYC Medical College. HMO5. A multi-center, single-arm, open label, phase I clinical trial to evaluate the efficacy and safety of processed hematopoietic stem cell preparations from unrelated or partially matched related donors in patients with poor prognosis hematologic disorders. Contact: Karen Seiter, MD. Phone: 914-285-8374.


Westchester Medical Center, New York Medical College. SMC-101-1020. Phase IIb study of thymoglobulin in transfusion dependent patients with RA or RAEB. Contact: Karen Seiter, MD. Phone: 914-493-8374.

The Western Pennsylvania Hospital. WPCI 2001-30 (Celgene # T-MDS-001). A randomized, multi-center, double-blind, placebo-controlled trial assessing the safety and efficacy of thalidomide for the treatment of anemia in red blood cell transfusion dependent patients with myelodysplastic syndromes. Contact: Laura Gibson, RN. Phone: 412-578-1034.

The Western Pennsylvania Hospital. WPCI 9614. Special Exception use of 5 Azacitidine in Myelodysplastic Syndromes. Sponsored by The National Cancer Institute. Contact: Laura Gibson, RN. Phone: 412-578-1034.
**Wilford-Hall Medical Center.** HMO4. A multi-center, non-randomized single-arm, phase I clinical trial to evaluate the safety and efficacy of processen bone marrow from mismatched related doors (HLA3/6 and 4/6) in acute or chronic leukemia patients. Contact: Major David Rine, MD, USAF, MC. Phone: 210-292-7391.

**William Beaumont Hospital.** T-MDS-001. A randomized multi-center, double-blind, placebo-controlled trial assessing the safety and efficacy of thalidomide for the treatment of anemia in red blood cell transfusion dependent patients with myelodysplastic syndromes. Contact: Ingrid Tibbits, RN, BSN, OCN.

**Winship Cancer Institute/Emory University.** SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIB study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: Elliott Winton, MD. Phone: 404-779-5851.

**CELGENE**

**T-MDS-001.** Phase III study of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. Contact: Sherrie Roberts. Phone: (190) 772-6960.

**Canadian Trials**

**Foothills Hospital/Calgary.** SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIB study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: Ramakrishnan Parameswaran, MD. Phone: 403-670-1564.

**Princess Margaret Hospital/Toronto.** SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIB study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: Joseph Brandwein, MD. Phone: 416-946-4595.

**Vancouver Hospital.** SMC-101-1020. An open-label, prospective, stratified, randomized, controlled, multicenter, phase IIB study of the impact of Thymoglobulin® therapy on transfusion needs of patients with early MDS. Contact: Thomas J. Nevill, MD. Phone: 604-875-4552.

**Canadian Inherited Marrow Failure Registry (CIMFR).** This is a study looking prospectively at the development of severe aplastic anemia, myelodysplastic syndromes and leukemia in patients with inherited marrow failure syndromes in Canada. Contact: Yigal Dror MD. Phone: (416) 813-5630.

**Canadian Inherited Marrow Failure Registry (CIMFR).** Hematopoietic stem cell transplantation in inherited marrow failure syndromes with severe aplastic anemia, myelodysplastic syndromes or leukemia. Contact: Yigal Dror MD. Phone: (416) 813-5630.

**European Trials**

**EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER**

**EORTC-19951.** EORTC. Phase III randomized study of amphotericin B-lipid complex initiated 72–84 hours versus 144–156 hours after onset of febrile episode in cancer patients with granulocytopenia and persistent unexplained fever refractory to antibacterials. Contact: B.E. DePauw, MD. Phone: 011-31-24-3614515.

**EORTC-06961.** Multicenter. Phase III randomized compariion of autologous peripheral-blood stem cell transplantation versus second intensive consolidation with high-dose cytarabine following common induction and consolidation in patients with poor-prognosis MDS and acute myeloegenous leukemia secondary (sAML) to MDS of more than 6 months’ duration. Contact: Theo De Witte, MD. Phone: 024-361-47-62 (Nijmegen, Netherlands).

**EORTC-06962.** Multicenter. Phase III randomized study to assess intensification of the conditioning regimen for allogeneic stem cell transplantation for leukemia or MDS with a high risk of relapse. Contact: Theo De Witte, MD. Phone: 024-361-47-62 (Nijmegen, Netherlands).

**EORTC-58921.** EORTC Children’s Leukemia Group. Phase III randomized comparison of IDA vs DHAD combined with ARA-C/VP-16 for induction and combined with high-dose ARA-C for intensification in children with newly diagnosed AML or Myelodysplastic Syndrome. Contact: Catherine Behar, MD. Phone: 011-03-26-78-77-89.

**EU-98010.** Medical Research Council’s Working Party on Leukemia in Adults and Children. Phase III randomized study of two induction chemotherapy regimens followed by two or three additional chemotherapy regimens or one or two additional chemotherapy regimen(s) with allogeneic BMT in children with de novo or secondary AML. Contact: E.C. Gordon-Smith, MD. Phone: 011-44-208-725-5448.

**EU-98031.** Riverside Haematology Group. Phase III randomized study of idarubicin and etoposide vs mitoxantrone, etoposide, and cytarabine as consolidation therapy in patients over 55 years old with AML in first complete remission. Contact: Graham Jackson, MD. Phone: 011-191-222-7632.

**EU-99029.** Swiss Institute for Applied Cancer Research. Phase III randomized study of antithymocyte globulin and cyclosporine versus best supportive care in patients with low or intermediate risk MDS. Contact: A. Tichelli, MD. Phone: 011-41-61-265-42-54.

**EU-20008.** Medical Research Council’s Working Party on Leukemia in Adults and Children. Phase III randomized study of induction chemotherapy with cytarabine, daunorubicin, and etoposide versus fludarabine and cytarabine and induction chemotherapy versus without filgrastim (G-CSF) or tretinoin in patients with high risk AML. Contact: D.W. Milligan, MD. Phone: 011-44-1-21-766-6611.

**EU-20016.** Medical Research Council’s Working Party on Leukemia in Adults and Children. Phase III randomized study of intensive versus non-intensive chemotherapy in older patients with acute myeloid leukemia or high risk MDS. Contact: Alan K. Burnett, MD. Phone: 011-222-742-375.

**AUSTRALIA**

**Peter McCullum Cancer Institute.** 00/58. A phase II multi-center, open label, dose escalation trial of the safety and efficacy of E2iR in adults with CMML. Contact: John Seymour, MD. Phone: +613-9656-1190.

**Peter McCullum Cancer Institute.** 00/66. A randomized study of the safety and efficacy of two dose schedule of gemtuzumab ologaminc in patients with intermediate II or high risk MDS. Contact: John Seymour. Phone: +613-9656-1190.

**ENGLAND**

**Kings College Hospital/Guys-Kings-Thomas School of Medicine.** Reduced intensity transplants in elderly with MDS and AML using Campath: (CD52) in the conditioning. Contact: Professor G.J. Musti. Phone: 004-4207-346-3080.

**Kings College Hospital/Guys-Kings-Thomas School of Medicine.** Thalidomide in good risk MDS. Contact: Professor G.J. Musti. Phone: 004-4207-346-3080.

**Kings College Hospital/Guys-Kings-Thomas School of Medicine.** GCSF and Epo versus supportive care. Contact: Professor G.J. Musti. Phone: 004-4207-346-3080.

**FRANCE**

**French MDS Group.** A phase II study of CPT 11 (irinotecan) in high risk MDS. Contact: V. Ribzeg, MD. Fax: 33-1-42-11-5270.
Lille University Hospital. Co-sponsored by the Groupe Français des Myélodysplasies. Phase II study of fludarabine phosphate in adult chronic myelomonocytic leukemia (CMML). Contact: P. Fenaux, MD, PhD. Fax: 33-320-44-40-94 (Lille).

Lille University Hospital. Intensive chemotherapy with dose-adjusted quinine in high-risk MDS with P-glycoprotein expression. Contact: P. Fenaux, MD, PhD. Fax: 33-320-44-40-94.

Lille University Hospital. Phase II study of intensive chemotherapy with mitoxantrone (MNX), cytarabine (Ara-C), and fludarabine (FAMP) in high-risk MDS without expression of the P-glycoprotein. Contact: P. Fenaux, MD, PhD. Fax: 33-320-44-40-94.


Groupe Hospitalier Cochin. Danatro in thrombopenic MDS. Contact: P. Fenaux, MD, PhD. Phone: 33-20-44-40-94 (Lille).

GERMANY


Hannover Medical School. Phase II study to evaluate thalidomide in the myelodysplastic syndromes. Contact: Arnold Ganser, MD. Phone: 049-511-5362-8205.

Hannover Medical School. SAKK 33/99. Antithymocyte globulin (ATG) and cyclosporine (CSA) to treat patients with myelo-dysplastic syndromes. A randomized phase III trial comparing ATG and CSA with best supportive care. Contact: Jakob Passweg, MD or Arnold Ganser, MD. Phone: 049-511-532-9257.

Heinrich-Heine University. Düsseldorf. HHU-1648. Phase II clinical trial of thalidomide for patients with myelodysplastic syndromes or idiopathic myelofibrosis. Contact: Norbert Gatterman, MD, PhD. Phone: 49-211-81-16500.

University Hospital Frankfurt/Main. ATG and CSA versus ATG in patients with MDS. Contact: Wolf K. Hoffman. Phone: +49-69-6307-5794.

University Hospital Frankfurt/Main. Treatment of patients with MDS with thalidomide. Contact: Wolf K. Hoffman. Phone: +49-69-6307-5794.

University Hospital Frankfurt/Main. All transretinoic acid in patients with MDS (5q- syndrome). Contact: Wolf K. Hoffman. Phone: +49-69-6307-5794.


University Hospital Frankfurt/Main. Intravenous low-dose decitabine versus supportive care in elderly patients with primary Myelodysplastic Syndrome (MDS) (>10% blasts or high-risk cytogenetics), secondary MDS or Chronic Myelomonocytic Leukemia (CML) who are not eligible for intensive therapy: an EORTC-German MDS Study Group randomized phase III study. Contact: Wolf K. Hoffman. Phone: +49-69-6307-5794.

GREECE

University of Patras Medical School. MDS-5. Treatment of patients younger than or equal to 65 years old with aggressive MDS or acute leukemia secondary to preexisting MDS with a combination of Topotecan and Aracytin or Idarubicin and Aracytn. A comparative randomized study. Contact: A. Symeonidis, MD, N. Zoumbos, MD. Phone: +30-610-999-247, +30-610-999526.

University of Patras Medical School. MDS-6. Treatment of elderly patients with aggressive MDS or acute leukemia secondary to preexisting MDS with Topotecan or Mitoxantrone and infusional standard dose of Aracytin. A comparative randomized study. Contact: A. Symeonidis, MD, N. Zoumbos, MD. Phone: +30-610-999-247, +30-610-999526.

University of Patras Medical School. MDS-7. Maintenance treatment of patients with proliferative or poor prognosis Chronic myelomonocytic leukemia with pulses of Topotecan and intermediate dose Aracytin or hydroxyurea. A comparative randomized study. Contact: A. Symeonidis, MD, N. Zoumbos, MD. Phone: +30-610-999-247, +30-610-999526.

University of Patras Medical School. MDS-8. Non myeloablative stem cell transplantation for patients 51-65 years old with aggressive MDS in first complete remission after 2 cycles of systemic chemotherapy. Contact: A. Symeonidis, MD, N. Zoumbos, MD. Phone: +30-610-999-247, +30-610-999526.

University of Patras Medical School. MDS-9. The role of amifostine as a cytoprotective agent for patients with aggressive MDS or acute leukemia superimposing a preexisting MDS with poor performance status or coexisting morbidity, treated with the standard chemotherapeutic protocols. Contact: A. Symeonidis, MD, N. Zoumbos, MD. Phone: +30-610-999-247, +30-610-999526.

University of Patras Medical School. MDS-10. Treatment of anemic patients with less aggressive MDS and low probability of response to erythropoeten plus G-CSF, with the combination of infliximab and escalated doses of erythropoiten. Contact: A. Symeonidis, MD, N. Zoumbos, MD. Phone: +30-610-999-247, +30-610-999526.

ISRAEL

Rabin Medical Center-Hasharon Hospital. Israel MDS-II (ICG). Low dose idarubicidin (I) and low dose G-CSF for Intermediate (IPSS I and II) and high risk patients. Contact: Mosh Mittelman, MD. Phone: 972-3-937-2361.

ITALY

Unit of Hematology and Stem Cell Transplantation, IRCCS “Casa Sollievo della Sofferenza” Hospital. A clinical trial with high dose, weekly, or b.i.w. administration of recombinant erythropoeten for the treatment of low risk myelodysplastic syndromes: focus on effects on anemia, fatigue and other psycho-social findings. Contact: Dr. Pellegrino. Phone: (0) 882-411389.

Unit of Hematology and Stem Cell Transplantation, IRCCS “Casa Sollievo della Sofferenza” Hospital. A phase III clinical trial for the treatment of transfusion-dependent, low-risk myelodysplastic syndromes with low dose thalidomide, alone or in combination with erythropoiten. Contact: Dr. Pellegrino. Phone: (0) 882-411389.

Unit of Hematology and Stem Cell Transplantation, IRCCS “Casa Sollievo della Sofferenza” Hospital. A clinical trial for the treatment of elderly patients with high risk myelodysplastic syndromes with low dose melphalan. Contact: Dr. Pellegrino. Phone: (0) 882-411389.

Unit of Hematology and Stem Cell Transplantation, IRCCS “Casa Sollievo della Sofferenza” Hospital. A clinical study on allogenic “mini” (non-myelosuppressive) peripheral blood stem cell transplantation in patients with high risk myelodysplastic syndromes aged up to 60. Contact: Dr. Pellegrino. Phone: (0) 882-411389.

KOREA

Samsung Medical Center. Manipulation of L-ascorbic acid level for the treatment of selected cases of MDS and AML. Contact: Chan H. Park. Phone: 011-822-341-3450.
Netherlands

University Medical Center St. Radboud. Study for younger patients with high-risk MDS/MD-S-AML. Contact: Theo de Witt, MD. Phone: 011-31-24-3618810.

Poland

Autologous or mini-allo bone marrow/haematopoietic stem cell transplantation in MDS patients. Contact: Aleksander B. Skotnicki MD, PhD.

Effect of thalidomide on clinical and haematological parameters in MDS patients. Contact: Aleksander B. Skotnicki, MD, PhD.

Scandinavia

Aarhus University Hospital. Effect of transfusion iron, iron chelation, and EPO on erythropoiesis in MDS patients. Contact: J. Ellegaard, MD. Phone: 45-89-49-75-58 (Denmark).

MAP Study. Diagnostic study on hypoplastic MDS, aplastic anemia and PHN. Contact: Torben Plesner, MD. Phone: 011-46-85-858-0000.

Scandinavian MDS Group. ATG-CyA 1999. Clinical phase II trial in which patients with RA and RAEB with <10% blasts and no sideroblasts are included. Treatment: ATG followed by cyclosporine A for six months. Contact: Eva Hellstrom-Lindberg, MD, PhD. Phone: 011-46-8-585-800-00.

VU University Medical Center/Amsterdam. HOVON 42. Randomized induction and post induction therapy in adult patients (<60 years of age) with AML, RAEB, RAEB-t with IPSS score greater or equal to 1.5. Contact: Dr. G.J. Ossenkoppele. Phone: +31-20-4442604.

VU University Medical Center/Amsterdam. HOVON 43. Randomized induction and post induction therapy in older patients (≥61 years of age) with AML, RAEB, RAEB-t. Contact: Dr. G.J. Ossenkoppele. Phone: +31-20-4442604.

VU University Medical Center/Amsterdam. In-vivo detection of apoptosis in MDS and AML with technetium 99mTc-Annexin-V (Apomate-TM). The role of EPO and G-CSF Contact: Dr.A.A. van de Loosdrecht. Phone: +31-20-4442604.

Scotland

Ninewells Hospital, Dundee/King’s College Hospital. UK MDS Therapy Working Group. A phase II/III trial of thalidomide therapy for low-risk MDS. Contact: David Bowen, MD. Phone: 011-44-1382-86011.

Ninewells Hospital University of Dundee. Identification of markers for early response to the combination of epoietin and G-CSF in the anemia of MDS. Contact: David Bowen, MD. Phone: 011-44-1382-660111.

South Africa

University of Cape Town and Groote Schuur Hospital. MDS/97. The effects of systemic cytokine modulation on haematopoiesis. Studies the effect of ciprofloxacin 500 mg BID, pentoxifylline 800 mg TID and dexamethasone 4 mg TID on blood parameters and clonogenic efficacy of progenitor cells. Contact: N. Novitzky, MD. Phone: 27-21-404-3073.

Spain

Hospital Universitario De Salamanca. SMD-FLAG-IDA-97. Induction therapy with FLAG-IDA with or without PBSC in high risk MDS patients and secondary AML. Contact: M.C. del Canizo, MD/J.F. San Miguel, MD. Phone: 011-34-923-291384.

Sweden

Huddinge University Hospital Karolinska Institutet. Scandinavian MDS-group ATG-CyA/99. Treatment of patients with myelodysplastic syndromes I and II (RA and RAEB) with ATG and cyclosporin A. Phase II trial enrolling patients with refractory anemia and RAEB with less than 10% blasts. Contact: Eva Hellstrom-Lindberg, MD, PhD. Phone: +46-8-585-80-000.

Huddinge University Hospital Karolinska Institutet. Nordic MDS-group Decitabine/02. Maintenance treatment with decitabine versus consolidation treatment with high-dose chemotherapy in patients with advanced MDS and MDS-AML, who have obtained CR with high dose chemotherapy. Randomized phase II study. Remission induction with 2+7. In CR randomization with conventional maintenance (2+7) and low dose decitabine. Contact: Eva Hellstrom-Lindberg, MD, PhD. Phone: +46-8-585-80-000.

Switzerland


Thailand

King Chulalongkorn Memorial Hospital. MDSCU 9803. To determine the association of RAS-mutation and occupational and environmental exposures in patients with AML and MDS. Contact: Tanin Intragumtornchai, MD. Phone: 011-622-2564564.

United Kingdom

King’s College. Mini and micro allogeneic transplants in MDS. Contact: Professor G.J. Multi. Phone: 44-207-346-3080.


King’s College. Reduced intensity transplant in elderly with MDS and AML using Campath: (CD52) in the conditioning. Contact: Siobhan Lim. Phone: 0207-346-3148.

King’s College. Phase I/II study of thalidomide therapy or patients with low risk MDS. Contact: Siobhan Lim. Phone: 0207-346-3148.

King’s College. An open label, phase 2 study to evaluate the efficacy and safety of the Farnesyl-transferase inhibitor ZANNESTRA (R115777) in subjects with high-risk MDS. Contact: Siobhan Lim. Phone: 0207-346-3148.

Royal Victoria Infirmary. RHG-AML97, EU-98031. Phase III randomized study of idarubicin and etoposide vs mitoxantrone, etoposide, and cytarabine as consolidation therapy in patients over 55 years old with acute myeloid leukemia in first complete remission. Contact: Graham Jackson, MD. Phone: 0191-222-7632.

Saint George’s Medical Center. MRC-LEUK-AML12CH, EU-98010. Phase III randomized study of two induction chemotherapy regimens or one or two additional chemotherapy regimen(s) with allogeneic bone marrow transplantation in children with de novo or secondary acute myeloid leukemia. Contact: E.C. Gordon-Smith, MD. Phone: 44-181-725-5448.

The Royal Bournemouth Hospital. Phase II trial of EB 1089, a vitamin D analogue with minimal effect of blood calcium for use in low-grade MDS in patients with Hb <10 g/dl, neutrophils <1x10^9/l or platelets <100x10^9/l. Contact: Professor T.J. Hamblin. Phone: 01-202-303626 (Bournemouth).

To submit information on your clinical trials for publication, you can fax (609-298-0590) us at the Foundation. Please include a contact person, a phone number, and if applicable, the trial number.
About the Foundation

The Myelodysplastic Syndromes Foundation was established by an international group of physicians and researchers to provide an ongoing exchange of information relating to MDS. Until the Foundation was set up, no formal working group had been devoted to MDS. During the past decade we have conducted seven international symposia—in Austria, England, the United States, Spain, Czech Republic, and Sweden. The Seventh International Symposium will be held May 15-18, 2003 in Paris, France.

One major role of the Foundation is our international information network. This network provides patients with referrals to Centers of Excellence, contact names for available programs, sharing of new research and treatment options, and extension of educational support to both physicians and patients. Ultimately, we hope to provide funding and oversight for international studies in MDS.

In response to the needs expressed by patients, families, and physicians, we have established patient advocacy groups.

The MDS Foundation is a publicly supported organization, exempt from federal income tax under section 501(C)(3) of the IRS code.

Our Website

The MDS Foundation Web page is for healthcare professionals, patients, and other interested people. The Professional Forum and the Patient Forum are integral parts of our Web site.

The Website is constantly being updated to better serve the needs of our patients, their families, and the physicians who treat them.

We welcome your suggestions.

Please visit us at http://www.mds-foundation.org
In Memorium

A memorial fund has been established in the name of
Mr. Dwight Agner
Donations have been made in Mr. Agner's memory by:
Robert and Dorothy Moore
Athens, GA
August Straub
Athens, GA
Robert Clements
Athens, GA
John and Patricia Lyndon
Athens, GA

A memorial fund has been established in the name of
Mr. John Anderholm
Donations have been made in Mr. Anderholm's memory by:
Hazel Marie Anderholm, Walnut Creek, CA

A memorial fund has been established in the name of
Mr. Rex Charles Batchelor, Jr.
Donations have been made in Mr. Batchelor's memory by:
City of Stockton City Manager's Office, Stockton, CA

A memorial fund has been established in the name of
Mr. Hubert S. Blaydes, Jr.
Donations have been made in Mr. Blaydes' memory by:
Barbara Cook
Roachdale, IN
Chauncey A. Blaydes, Jr.
Ladoga, IN
Richard M. and Karen Bennett III
Indianapolis, IN
Carol J. Shedd
Fort Wayne, IN
Nancy J. Springer
Wolcottville, IN
Jean Baehner Blaydes
Coatesville, IN
Tilden and Cathy Mendelson
Indianapolis, IN
Indiana University Student Union
Indianapolis, IN
Forest and Lydia White
Linden, IN
Donald and Cara Frosch
Coatesville, IN
Martha Vogt
Carmel, IN

A memorial fund has been established in the name of
Ms. Lucy Caiazzo
Donations have been made in Ms. Caiazzo's memory by:
Anthony Perotta
Brooklyn, NY
Blanche Cudzilo
Ellicott City, MD
Angela Zinnel
San Antonio, TX
Craig Romaszka
Howell, NJ

Suzanne Fleischman Memorial Fund for Patient Advocacy

A fund has been established by the Myelodysplastic Syndromes Foundation in memory of Suzanne Fleischman. Contributions may be sent to the Foundation with a notation designating the Suzanne Fleischman Memorial Fund for Patient Advocacy.

New donations have been made by:
Daniel and Sandra Linn, La Jolla, CA
Fay Wanetick, Pittsburgh, PA
Edward Fleischman, Coronado, CA

A memorial fund has been established in the name of
Mr. Irving Blickstein
Donations have been made in Mr. Blickstein's memory by:
Geoff and Sandy Goldworm, Cherry Hill, NJ

A memorial fund has been established in the name of
Miss Kayla Nicole Byers
Donations have been made in Miss Byers' memory by:
Willie and Jackie Beauregard
Kentwood, MI
Don and Barb James
Grand Rapids, MI
Christopher and Deanna Collins
Dearborn, MI
Troy and Robyn Turnbull
Grand Rapids, MI
Dan and Patti Brink
Grand Rapids, MI
Tom Vaughn
Paw Paw, MI
Neil and Cindy Kimball
Grand Rapids, MI
Ruth Nelson
Grand Rapids, MI
Irving Leonard
Willmette, IL
Sue Stoddard
Grand Rapids, MI
Barbara Fessell and Marv Huttena
Grand Rapids, MI
Mary Murtland
Morley, MI
Ted Heerja
Wyoming, MI
James and Susan Rex
Grand Rapids, MI
Ron and Rachel Geysbeek
Comstock Park, MI
Chris Conklin
Lowell, MI
Harvey and Georgiann Greeman
Ada, MI
The Behler-Young Company
Grand Rapids, MI
Ladonna Reinke and Fred Stevens
Wyoming, MI
The Knutson Family
Kentwood, MI
Anne T. Markaity
Grand Rapids, MI
St. John Vianney School Staff
Wyoming, MI
Ed, Joan and Becky Stein
Kentwood, MI
Jason Fritsma
Grand Rapids, MI
Jeffrey and Ellen Kruggel
Caledonia, MI
Mark and Barbara Dobbs
Grand Rapids, MI
West Michigan Heart
Grand Rapids, MI
Mr. and Mrs. James Snell
Ludington, MI

A memorial fund has been established in the name of
Mr. Dennis Cadwallader
Donations have been made in Mr. Cadwallader's memory by:
Vivian Cadwallader, Shoreline, WA

A memorial fund has been established in the name of
Ms. Lucy Caiazzo
Donations have been made in Ms. Caiazzo's memory by:
Anthony Perotta
Brooklyn, NY
Blanche Cudzilo
Ellicott City, MD
Angela Zinnel
San Antonio, TX
Craig Romaszka
Howell, NJ

A memorial fund has been established in the name of
Mrs. Jeanette Calbick
Donations have been made in Mrs. Calbick's memory by:
Alan W. Heim, Wasilla, AK
Membership Information

The MDS Foundation would like to have you as a member. Membership is US$35 a year for physicians and other professionals. Patients, their families, and others interested in MDS may join at the reduced rate of $20.

Membership benefits include quarterly issues of the MDS News, a special subscription rate of $105 for Leukemia Research (a substantial discount from the current subscription rate of $1,193), and the worldwide Centers of Excellence patient referral service.

If you would like additional information, please contact us at:

The MDS Foundation
P.O. Box 353
36 Front Street
Crosswicks, NJ 08515

Phone: 1-800-MDS-0839
Fax: 609-298-0590
Outside the US only:
609-298-1035

A memorial fund has been established in the name of
Mr. Ed Cohen
Donations have been made in Mr. Cohen's memory by:
Eugene and Meta Lee
Davie, FL
Roberta Berly
Pembroke Pines, FL

A memorial fund has been established in the name of
Mrs. Lois Cullen
Donations have been made in Mrs. Cullen's memory by:
Nitaya Churanakoses
Phoenix, AZ
Sara and Walter Komaromi
Ithaca, NY
Margaret Cole
La Canada, CA
Bob and Madeline Wallace
Redwood City, CA
Native Daughters of the Golden West Bonita Parlor No. 10
Menlo Park, CA
Carl and Shirley Kukkonen
Phoenix, AZ
Doris Considine
Oakdale, CA
Georgia Harjes
Palo Alto, CA
Carl and Shirley Ivelich
Watsonville, CA
John and Shirley Ivellich
Redwood City, CA
Gail Roy, CA
Steve and Margo Rettig
Pasadena, CA
Richard and Nancy Codiga
Carlsbad, CA
Patty Cullen

A memorial fund has been established in the name of
Mr. Jerry G. Dashe
Donations have been made in Mr. Dashe's memory by:
Jerrol L. Harris
San Mateo, CA
Ann Dashe
La Jolla, CA
Richard Friedkin
Tarzana, CA

A memorial fund has been established in the name of
Mr. Joseph L. Davito
Donations have been made in Mr. Davito's memory by:
Chris Berta Family
Seattle, WA
James Viano Family
Braidwood, IL
Mark Corcoran Family
Rockford, IL
Donald Born
Coal City, IL
Marge Van Duyn
Wilmington, IL
Greg and Jackie Washburn
Coal City, IL
Shirley Marsaglia
Coal City, IL
Bob and Helen McCullie
Joliet, IL
Bill Davito Family
Coal City, IL
Jerry McCullie Family
Coal City, IL
Art and Claire Nyc
Morris, IL
Lisa Smith
Coal City, IL
Darrell and Marchene Dolmage
Morris, IL
Shirley Boero
Coal City, IL
Joe Pierard Family
Coal City, IL

A memorial fund has been established in the name of
Mr. Donald Faulkner
Donations have been made in Mr. Faulkner's memory by:
Roy McCoy, Knoxville, TN

A memorial fund has been established in the name of
Ms. Jean Follrath
Donations have been made in Ms. Follrath's memory by:
Jackie Cumpton, Rose Hopp,
Mark Howington Pat Podriznik,
and Charlotte Underwood
Snellville, GA

A memorial fund has been established in the name of
Mr. Sam Friedman
Donations have been made in Mr. Friedman's memory by:
William Friedman, Litchfield, CT

A memorial fund has been established in the name of
Mrs. Sylvia Kaplan Gardarian
Donations have been made in Mrs. Gardarian's memory by:
Jack and Eunice Greenstein
Los Angeles, CA
Bea Steelman
Los Angeles, CA
Marvin and Tamara Greenstein
Beverly Hills, CA
Morton and Rose Yates
Los Angeles, CA
N. Yee
Unified School District
Los Angeles, CA

continued on page 24
In Memorium (continued from page 23)

A memorial fund has been established in the name of
Mr. J. Thom George
Donations have been made in Mr. George’s memory by:
Edward & Dianne McKinney, Baltimore, MD

A memorial fund has been established in the name of
Mr. Herman G. Green
Donations have been made in Mr. Green’s memory by:
Sid and Norma Weinberg
Margate, NJ
Jerry and Reenie Green
Wildwood Crest, NJ

A memorial fund has been established in the name of
Mr. Len Hirschfeld
Donations have been made in Mr. Hirschfeld’s memory by:
Geoff and Sandy Goldworm, Cherry Hill, NJ

A memorial fund has been established in the name of
Mr. John Horner
Donations have been made in Mr. Horner’s memory by:
Janet L. Heuer
Sanford, FL
Richard C. Steck & Judith A. Janofsky
Roswell, GA
Greene, Dycus & Co., PA
Sanford, FL
Doris Phillips
Sanford, FL
Kimberly A. Gray Xentury City Development Company
Orlando, FL
Thomas Hunt
Longwood, FL
Lynda and S. Kirby Moncrief
Sanford, FL
Arthur and Irene Harris
Sanford, FL
Earl and Geraldine Weldon
Sanford, FL
Rick and Diane Herring
Atlanta, GA
Geraldine Harris
Belton, TX

A memorial fund has been established in the name of
Ms. Maxine Hutchens
Donations have been made in Ms. Hutchens’ memory by:
Margaret Breyer
Princeton, NJ
Stancia Kalmus
Deerfield, IL
Mark and Nancy Travers
St. Charles, IL
Benjamin and Joyce Schlesinger
Bethesda, MD
Debbie Yangass
Hanover Park, IL
Clark Engineers, Inc.
Peoria, IL

A memorial fund has been established in the name of
Mr. Daniel Jackson
Donations have been made in Mr. Jackson’s memory by:
Michael and Freda Mrvosh
Carol Teel
Dunbar, WV
Charleston, WV
Stanley and Linda Miller
Sandra Stewart
St. Albans, WV
St. Albans, WV

A memorial fund has been established in the name of
Mr. Harry Kaercher
Donations have been made in Mr. Kaercher’s memory by:
Dolores Wdman-Cohen, Marlton, NJ

A memorial fund has been established in the name of
Mrs. Barbara Jo Kirby
Donations have been made in Mrs. Kirby’s memory by:
Sean McGrath, Mounds View, MN

A memorial fund has been established in the name of
Mr. Frank Kiss
Donations have been made in Mr. Kiss’ memory by:
James and Catherine Kiss, Milwaukee, WI

A memorial fund has been established in the name of
Mr. Michael J. Lakis
Donations have been made in Mr. Lakis’ memory by:
Theodore and Alyce Halchak
David and Geraldine Cunningham
Upper Montclair, NJ
Ashaway, RI
Richard K. Milin
James and Carolyn Agar
New York, NY
McAllen, TX
Dean T. Pappas
Leon Segall
Northbrook, IL
Montgomery, AL
June Inderwies
Leonard and Annette St. Pierre
Newark, NJ
Aiken, SC
Vivian Reemer
W.B. Mason
New City, NY
Westerly, RI
Charles and Nancy Knapp
Michael and Maryann Beckerich
Suffern, NY
Piermont, NY
Josephine Pstane
John Gerald
Flushing, NY
Boynton Beach, FL
Ray and Donna Klocke
Karen Giannelli
Alamo, CA
Newark, NJ
George and Penny Leonard
Catalytic Generators
Congers, NY
Nortfolk, VA
Christine Amalfi
Glenn Bryant, Jr.
Roseland, NJ
Cincinnati, OH
James Schindwine

A memorial fund has been established in the name of
Mr. Ralph R. Lasater
Donations have been made in Mr. Lasater’s memory by:
Bruce and Sara Brandaleone, Potomac, MD

A memorial fund has been established in the name of
Mr. Carl Henry Luerman
Donations have been made in Mr. Luerman’s memory by:
Larry and Rosemary Arp, Boulder, CO
A memorial fund has been established in the name of
Mr. Alan MacDowell
Donations have been made in Mr. MacDowell’s memory by:
David and Linda Davenport
Cheyenne, WY
Joseph Verillo
Apple Music Company
Southampton, CT
Meredith and Ralph Mann
Southampton, CT
Julia and George Sacheck
Plantsville, CT
Ann and Mark Izzo
Cheshire, CT
Southington Post Office
Southington, CT
John and Holly Henry
Morgan Hill, CA
Donald Markham West
Sunnyvale, CA
Mary Moffat
Southington, CT
Richard and Rosanne Magnoli
Southington, CT
Florence MacDowell
Southington, CT
Joseph and Angela Ceruti
Southington, CT
Mark and Lucy Carbone
Southington, CT
Raymond and Debra DeLouise
Cheshire, CT
Phillip and Dorothy Mucha
Avon, CT
Thomas and Gina Ricard
Cheshire, CT

A memorial fund has been established in the name of
Mr. Jim McDonough
Donations have been made in Mr. McDonough’s memory by:
Geoff and Sandy Goldworm, Cherry Hill, NJ

A memorial fund has been established in the name of
Mrs. Mary Lee Neubauer
Donations have been made in Mrs. Neubauer’s memory by:
The Seppelt Family
Clinton, IA
Gary and Nora Oleson
Clinton, IA
Donald and Linda Hughes
Bryant, IA
Mary Jane Case
Camanche, IA
Donald and Joyce Humphrey
Kellogg, IA
Dirk E. Johnson
Sycamore, IL
Susan B. Peters
Clinton, IA
Robert and Jane Taylor
Clinton, IA
Gail Gonzales
Brookfield, IL
Betty Alvarez
Hudson, FL
Lois J. Mussett
Mankato, MN
Grey Woodman
Clinton, IA
June Vanderveen
Alexandria, VT
Nancy Malloy
Somerville, MA
George and Nancy Seidler
Peoria, IL
Dwight and Barbara Price
Clinton, IA
Marian Irey
Clinton, IA
Eugene Bowker
Clinton, IA
Barbara Hagenson
Clinton, IA

A memorial fund has been established in the name of
Mrs. Virginia Price
Donations have been made in Mrs. Price’s memory by:
Karen and Jeffrey Grabill, Chicago, IL

A memorial fund has been established in the name of
Mr. John Ray
Donations have been made in Mr. Ray’s memory by:
Peggy Vanbrocklin and Paula Sibal
Saranac, MI
Patricia Knight
Grandville, MI
Diane Thomas
Jenison, MI
Mary Fues
Rockford, MI
Cheryl Burns
Grand Rapids, MI
Paul and Kelli Kovack
Belmont, MI
J. Craig Mulligan
Grand Rapids, MI
Constance Ward
Kentwood, MI

A memorial fund has been established in the name of
Mr. David L. Rigby
Donations have been made in Mr. Rigby’s memory by:
Amy Seamans
Tallahassee, FL
Zahma D. Wiler
Tallahassee, FL

A memorial fund has been established in the name of
Ms. Sybil Saverence
Donations have been made in Ms. Saverence’s memory by:
Ross and Nancy Crolius
Ardsley, NY
Lorraine Keane
New York, NY
Patricia and Emile Steiner
New York, NY
Karen Dixon
New York, NY
Joseph and Carolyn Sielski
Allendale, NJ
Mary Meyers
Elmwood Park, NJ
Irwin L. Reese
New York, NY
Jean M. Braham Myers
Lake Hopatcong, NJ
Elaine Flynn Young
New York, NY

A memorial fund has been established in the name of
Mr. Norman A. Sayer
Donations have been made in Mr. Sayer’s memory by:
Gilles and Diane Carrier, Methuen, MA

A memorial fund has been established in the name of
Mr. Loren Schoof
Donations have been made in Mr. Schoof’s memory by:
Joe and Ban Peterson, Sunnyvale, CA

A memorial fund has been established in the name of
Mr. Alvan Sievers
Donations have been made in Mr. Sievers’ memory by:
Charles and Ann Schoeffler, Rochester, NY

A memorial fund has been established in the name of
Mr. Willis Shiffer
Donations have been made in Mr. Shiffer’s memory by:
Thomas R. and Sharon C. Grimes
South Bend, IN
Walter J. and Nancy M. Rudge
Granger, IN
Walter and Margaret Rudge
Granger, IN
continued on page 26
A memorial fund has been established in the name of
Mr. Richard Stein
Donations have been made in Mr. Stein's memory by:
Joan and Donald Larson
Bothell, WA
Stephen Hutzler and Denise Rogers
San Jose, CA

A memorial fund has been established in the name of
Mrs. Sidonie Stolz
Donations have been made in Mrs. Stolz's memory by:
Eldon and Frieda Nyhart
Indianapolis, IN
Oskar and Therese Jochum
Mooresville, IN
Sue Crepeau
Warren, MI
Ed and Betty Poedtke
Union Grove, WI
Bernardine Dubrovich
Macomb, MI
Ann Reznik
Macomb, MI
Dolores Dickey
Shelby Township, MI
Jeff and Donna Shoemaker
Rochester Hills, MI
Rick and Jill Schwartz
Lake Wylie, SC
Cy Ann M. Martin
Neenah, WI

A memorial fund has been established in the name of
Mr. Albert J. Strohm
Donations have been made in Mr. Strohm’s memory by:
Perry Ann, Woody and Scott Woodell
Springdale, AR
Tim and Sandy Modesitt
Naperville, IL
Lynn and Ron Samuel
Naperville, IL
William and Susan Reneau
Missoula, MT
J. G. Holding
Warren, PA
James Campbell
Batavia, IL

A memorial fund has been established in the name of
Ms. Marie Wandrie
Donations have been made in Ms. Wandrie's memory by:
Kristen and John Focht, Jr.
Collegeville, PA

--

SuperGen has provided the MDS Foundation with unrestricted educational grants to support the Foundation’s work.
Gifts to the Foundation

The MDS Foundation relies entirely on gifts and membership fees to further its work. We would like to acknowledge the generosity of the following individuals and organizations that have recently provided gifts to the Foundation:

John and Carol Bennett, Family Fund 1
Rochester Area Community Foundation
Rochester, NJ

Mr. George Allen, Ellsworth, ME

Act II Playhouse Ltd., Ambler, PA

Fannie Mae Matching Gifts Program
Matching Gift by Mr. James W. Hester
Princeton, NJ

Ms. Alice J. Lorentz, Mercer Island, WA

Mr. and Mrs. Rick and Mary Monical
The Woodlands, TX

Mr. and Mrs. Jimmy and Deena Shelley
Hartsville, SC

Mr. and Mrs. Ronald and Fay Ante
Cincinnati, OH

United Way of New York City
New York, NY

Lawrence S. Kolinski
Norkol, Inc., Northlake, IL

Verizon North Incorporated, San Angelo, TX

Mrs. Sylvia B. Brenner, Chestnut Hill, MA

United Way of Delaware, Wilmington, DE

First Energy Corporation, Akron, OH

Ms. Alice J. Lorentz, Mercer Island, WA

The MDS Foundation is very grateful for the heartfelt support of its donors. Our work as a non-profit organization depends on public funding. If you would like to contribute, or if you have a unique idea of your own, please write to us at PO Box 353, 36 Front Street, Crosswicks, NJ 08515 or call us at 1-800-MDS-0839.
Patient Services

The MDS Foundation is pleased to share with our patients and their families that flight services are available within the continental United States to assist with special medical needs.

AirLifeLine is a nationwide organization of over 1,100 pilots who are caring, committed and compassionate individuals donating their time, aircraft and fuel to provide free transportation for patients in financial need.

Generally, the criteria for patient travel with us are:

• The patient must be ambulatory or be mobile enough to board and exit the aircraft. The patient must be able to sit in a seat and wear a seatbelt. Patient may bring along a family member or a support person to assist them. In the case of a child, both parents may travel.

• The patient should be medically stable and able to fly in an unpressurized aircraft. Our pilots are not medically trained and their planes are not medically equipped. Oxygen is allowed with the pilot's consent.

• The patient must demonstrate financial need and be unable to afford other means of commercial transportation. We do waive this requirement for financial need if the patient has a time critical situation such as an organ transplant.

• The patient's flight should be less than approximately 1,000 from his or her home to the medical destination. The average mission is between 250–500 miles. However, we can coordinate flights up to 1,000 miles one way.

It is the mission of Angel Flight to ensure that no financially needy patient is denied access to distant, specialized treatment for lack of means of air transportation.

AirLifeLine 800-446-1231
Angel Flight 800-296-1191
Corporate Angel Network 914-328-1313
National Patient Travel Center 800-296-1217

Thank You to Our Pharmaceutical Partners

We would like to thank our pharmaceutical partners for their support of the Foundation and its work. They have contributed in the form of unrestricted educational grants, which support not only this newsletter but also the development of the MDS home page on the World Wide Web, the Centers of Excellence program, continuing medical education programs, the Patient Registry, and the dissemination of patient information.

A Living Endowment

A Living Endowment donation has been made in honor of:

Ms. Jennifer Horowitz
This donation has been submitted by:
Andrew and Ina Feuerstein, Brooklyn, NY

Many families are affected by living with the reality of MDS. There is an extraordinary way to contribute to the MDS Foundation and support our mission of working as a resource for patients, families, and healthcare professionals.

A commitment to donate to the Foundation on occasions of loss, birthdays and anniversary remembrances can be made. Honor your friends or family members on these occasions with a donation, and The MDS Foundation will send an acknowledgment to the recipient, recognizing the occasion.

The MDS Foundation is grateful for community support. Our work as a non-profit organization depends on public funding. If you would like to contribute in this way, please write to us at PO Box 353, 36 Front Street, Crosswicks, NJ 08515, or call us at 1-800-MDS-0839.